Balance Sheet
Accounts PayablesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLong-Term Deferred TaxMinority InterestNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Jin Medical International (ZJYL) over the last 3 years, with Q3 2024 value amounting to $44.8 million.

  • Jin Medical International's Liabilities and Shareholders Equity rose 3611.92% to $44.8 million in Q3 2024 from the same period last year, while for Mar 2025 it was $77.7 million, marking a year-over-year increase of 4429.24%. This contributed to the annual value of $44.8 million for FY2024, which is 3611.92% up from last year.
  • Per Jin Medical International's latest filing, its Liabilities and Shareholders Equity stood at $44.8 million for Q3 2024, which was up 3611.92% from $32.9 million recorded in Q3 2023.
  • Over the past 5 years, Jin Medical International's Liabilities and Shareholders Equity peaked at $44.8 million during Q3 2024, and registered a low of $20.9 million during Q3 2022.
  • Over the past 3 years, Jin Medical International's median Liabilities and Shareholders Equity value was $32.9 million (recorded in 2023), while the average stood at $32.9 million.
  • As far as peak fluctuations go, Jin Medical International's Liabilities and Shareholders Equity surged by 5713.55% in 2023, and later soared by 3611.92% in 2024.
  • Over the past 3 years, Jin Medical International's Liabilities and Shareholders Equity (Quarter) stood at $20.9 million in 2022, then surged by 57.14% to $32.9 million in 2023, then soared by 36.12% to $44.8 million in 2024.
  • Its Liabilities and Shareholders Equity stands at $44.8 million for Q3 2024, versus $32.9 million for Q3 2023 and $20.9 million for Q3 2022.